Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference
Candel Therapeutics, a clinical stage biopharmaceutical company focused on viral immunotherapies, announced that CEO Paul Peter Tak will participate in a virtual fireside chat at B. Riley Securities’ 3rd Annual Oncology Conference. The event is scheduled for January 19, 2023, at 11:30 am EST. A live webcast will be available on the company’s website, with an archive accessible for 90 days post-event. Candel is known for its innovative approaches to cancer treatment, employing genetically modified viruses to enhance anti-tumor immune responses.
- None.
- None.
NEEDHAM, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in a virtual fireside chat at B. Riley Securities’ 3rd Annual Oncology Conference. Details are as follows:
Format: Virtual Fireside Chat
Date/Time: Thursday, January 19, 2023, at 11:30 am EST
A live webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section on Candel.com. A replay of the webcast will be archived for up to 90 days following the presentation date.
About Candel Therapeutics
Candel is a clinical stage biopharmaceutical company focused on helping patients fight cancer with viral immunotherapies that elicit a systemic anti-tumor immune response. Candel’s engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens while creating a pro-inflammatory microenvironment at the site of injection. Candel has established two clinical stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform. The enLIGHTEN™ Discovery Platform is the first systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit www.candeltx.com.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, include key data readout milestones; expectations regarding the therapeutic benefit of its programs; and expectations regarding cash runway and expenditures. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, and strategic plans for the Company’s business and product candidates, and other risks identified in the Company’s SEC filings, including the Company’s most recent Quarterly Report on Form 10-Q filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Media Contact
Cassidy McClain
Account Director
Evoke Canale
Cassidy.McClain@evokegroup.com
(619) 694-6291
Investor Contact
Sylvia Wheeler
Principal
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
FAQ
What event will Candel Therapeutics participate in on January 19, 2023?
Who is the CEO of Candel Therapeutics?
What is the focus of Candel Therapeutics' research?
Where can I watch the Candel Therapeutics fireside chat?
How long will the webcast of Candel Therapeutics' presentation be available?
